Search Results - "Piehl, Fredrik"

Low-dose rituximab should be used for treating MS in resource-limited settings: Yes by Piehl, Fredrik, Mathew, Thomas

Get full text

Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod by Piehl, Fredrik, Kockum, Ingrid, Khademi, Mohsen, Blennow, Kaj, Lycke, Jan, Zetterberg, Henrik, Olsson, Tomas

“…Background: Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in multiple sclerosis (MS). Objective: To determine the…”
Get full text

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein by Novakova, Lenka, Zetterberg, Henrik, Sundström, Peter, Axelsson, Markus, Khademi, Mohsen, Gunnarsson, Martin, Malmeström, Clas, Svenningsson, Anders, Olsson, Tomas, Piehl, Fredrik, Blennow, Kaj, Lycke, Jan

“…To examine the effects of disease activity, disability, and disease-modifying therapies (DMTs) on serum neurofilament light (NFL) and the correlation between…”
Get full text

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study by He, Anna, Merkel, Bernd, Brown, James William L, Zhovits Ryerson, Lana, Kister, Ilya, Malpas, Charles B, Sharmin, Sifat, Horakova, Dana, Kubala Havrdova, Eva, Spelman, Tim, Izquierdo, Guillermo, Eichau, Sara, Trojano, Maria, Lugaresi, Alessandra, Hupperts, Raymond, Sola, Patrizia, Ferraro, Diana, Lycke, Jan, Grand'Maison, Francois, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Larochelle, Catherine, Svenningsson, Anders, Petersen, Thor, Grammond, Pierre, Granella, Franco, Van Pesch, Vincent, Bergamaschi, Roberto, McGuigan, Christopher, Coles, Alasdair, Hillert, Jan, Piehl, Fredrik, Butzkueven, Helmut, Kalincik, Tomas

“…High-efficacy therapies in multiple sclerosis are traditionally used after unsuccessful treatment with first-line disease modifying therapies. We hypothesised…”
Get full text

Rituximab treatment for multiple sclerosis by Ineichen, Benjamin V, Moridi, Thomas, Granberg, Tobias, Piehl, Fredrik

“…Rituximab, a chimeric anti-CD20-antibody, attracts increasing attention as a treatment option for multiple sclerosis (MS). Apart from smaller controlled…”
Get full text

Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis by Brauner, Susanna, Eriksson-Dufva, Ann, Hietala, Max Albert, Frisell, Thomas, Press, Rayomand, Piehl, Fredrik

“…Use of biologic agents in generalized myasthenia gravis is generally limited to therapy-refractory cases; benefit in new-onset disease is unknown. To assess…”
Get more information

Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes by Piehl, Fredrik, Hillert, Jan

Get full text

Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies by Dunn, Nicky, Juto, Alexander, Ryner, Malin, Manouchehrinia, Ali, Piccoli, Luca, Fink, Katharina, Piehl, Fredrik, Fogdell-Hahn, Anna

“…Background: Rituximab is a chimeric monoclonal anti-CD20 B-cell-depleting antibody increasingly used off-label in multiple sclerosis (MS). The clinical…”
Get full text

Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis by Novakova, Lenka, Axelsson, Markus, Khademi, Mohsen, Zetterberg, Henrik, Blennow, Kaj, Malmeström, Clas, Piehl, Fredrik, Olsson, Tomas, Lycke, Jan

“…Cerebrospinal fluid (CSF) biomarkers can reflect different aspects of the pathophysiology of relapsing‐remitting multiple sclerosis (RRMS). Understanding the…”
Get full text

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis by Howard, James F, Bril, Vera, Burns, Ted M, Mantegazza, Renato, Bilinska, Malgorzata, Szczudlik, Andrzej, Beydoun, Said, Garrido, Francisco Javier Rodriguez De Rivera, Piehl, Fredrik, Rottoli, Mariarosa, Van Damme, Philip, Vu, Tuan, Evoli, Amelia, Freimer, Miriam, Mozaffar, Tahseen, Ward, E Sally, Dreier, Torsten, Ulrichts, Peter, Verschueren, Katrien, Guglietta, Antonio, de Haard, Hans, Leupin, Nicolas, Verschuuren, Jan J.G.M

“…OBJECTIVETo investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with…”
Get full text

Gsta4 controls apoptosis of differentiating adult oligodendrocytes during homeostasis and remyelination via the mitochondria-associated Fas-Casp8-Bid-axis by Carlström, Karl E., Zhu, Keying, Ewing, Ewoud, Krabbendam, Inge E., Harris, Robert A., Falcão, Ana Mendanha, Jagodic, Maja, Castelo-Branco, Gonçalo, Piehl, Fredrik

“…Arrest of oligodendrocyte (OL) differentiation and remyelination following myelin damage in multiple sclerosis (MS) is associated with neurodegeneration and…”
Get full text

Differential effects on blood and cerebrospinal fluid immune protein markers and kynurenine pathway metabolites from aerobic physical exercise in healthy subjects by Isung, Josef, Granqvist, Mathias, Trepci, Ada, Huang, Jesse, Schwieler, Lilly, Kierkegaard, Marie, Erhardt, Sophie, Jokinen, Jussi, Piehl, Fredrik

“…Mounting evidence shows that physical exercise modulates systemic inflammation. However, its effect on cerebrospinal fluid (CSF) immune-marker profiles in man…”
Get full text

Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry by Spelman, Tim, Frisell, Thomas, Piehl, Fredrik, Hillert, Jan

“…Objective: To compare treatment effectiveness and persistence in relapsing-remitting multiple sclerosis patients who initiated rituximab versus glatiramer…”
Get full text

Risk factors for amyotrophic lateral sclerosis by Ingre, Caroline, Roos, Per M, Piehl, Fredrik, Kamel, Freya, Fang, Fang

“…Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease. It is typically fatal within 2-5 years of symptom onset. The incidence of ALS is…”
Get full text

Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes by Carlström, Karl E., Ewing, Ewoud, Granqvist, Mathias, Gyllenberg, Alexandra, Aeinehband, Shahin, Enoksson, Sara Lind, Checa, Antonio, Badam, Tejaswi V. S., Huang, Jesse, Gomez-Cabrero, David, Gustafsson, Mika, Al Nimer, Faiez, Wheelock, Craig E., Kockum, Ingrid, Olsson, Tomas, Jagodic, Maja, Piehl, Fredrik

“…Dimethyl fumarate (DMF) is a first-line-treatment for relapsing-remitting multiple sclerosis (RRMS). The redox master regulator Nrf2, essential for redox…”
Get full text

Correlation between leukocyte phenotypes and prognosis of amyotrophic lateral sclerosis by Cui, Can, Ingre, Caroline, Yin, Li, Li, Xia, Andersson, John, Seitz, Christina, Ruffin, Nicolas, Pawitan, Yudi, Piehl, Fredrik, Fang, Fang

“…The prognostic role of immune cells in amyotrophic lateral sclerosis (ALS) remains undetermined. Therefore, we conducted a longitudinal cohort study including…”
Get full text

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels by Manouchehrinia, Ali, Piehl, Fredrik, Hillert, Jan, Kuhle, Jens, Alfredsson, Lars, Olsson, Tomas, Kockum, Ingrid

“…Blood Neurofilament light chain (NfL) has been suggested as a promising biomarker in several neurological conditions. Since blood NfL is the consequence of…”
Get full text

Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression by Romme Christensen, Jeppe, Börnsen, Lars, Ratzer, Rikke, Piehl, Fredrik, Khademi, Mohsen, Olsson, Tomas, Sørensen, Per Soelberg, Sellebjerg, Finn

“…Pathology studies of progressive multiple sclerosis (MS) indicate a major role of inflammation including Th17-cells and meningeal inflammation with ectopic…”
Get full text

Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab by Jonsson, Dagur Ingi, Pirskanen, Ritva, Piehl, Fredrik

“…Highlights; • Tocilizumab is an anti-interleukin-6-receptor humanized monoclonal antibody. • Tocilizumab was effective in two patients with refractory…”
Get full text

Dynamics of cerebrospinal fluid levels of matrix metalloproteinases in human traumatic brain injury by Minta, Karolina, Brinkmalm, Gunnar, Al Nimer, Faiez, Thelin, Eric P., Piehl, Fredrik, Tullberg, Mats, Jeppsson, Anna, Portelius, Erik, Zetterberg, Henrik, Blennow, Kaj, Andreasson, Ulf

“…Matrix metalloproteinases (MMPs) are extracellular enzymes involved in the degradation of extracellular matrix (ECM) proteins. Increased expression of MMPs…”
Get full text